Ministry of Health of Russia has granted Natsimbio Holding an authorization to conduct clinical trials of the first in Russia and the second in the world combined vaccine for the prevention of influenza and coronavirus infection - Ultrix Combi. Safety and tolerability of the drug will be tested with the participation of 370 patients. Drug is being developed...

Nextgen Biotech plans to launch a program of inbound medical tourism to Russia for patients from the People's Republic of China. Company will offer Chinese citizens treatment of chronic lower limb ischemia with the drug Neovasculgen developed by the company. After the completion of clinical trials of the drug for other indications, domestic and foreign patie...

Shareholders of Artgen approved dividends for 2023 in the amount of ₽1.2 per ordinary share. The last day of purchase of securities to receive dividends is June 14, 2024. Dividend yield may amount to 1.19%.

Genotarget, a startup belonging to Artgen Biotech, has completed preclinical studies of a new gene therapy drug GTDF102 for the treatment of muscular dystrophy. In studies conducted on mice with a disease model, it was possible to achieve the synthesis of the normal protein dysferlin in an amount sufficient to improve the condition of muscle tissue. Genotarg...